Caution, this is an AI generated summary based on literature. This may have errors, see here for more.
Please share your feedback with us.
hsa-mir-326: Hsa-mir-326 is a microRNA that has been identified as differentially expressed in chronic myeloid leukemia (CML) patients, showing a down-regulation in resistant cases as compared to responders [PMC2743636]. This microRNA has been associated with significant biological effects in non-small cell lung cancer (NSCLC) animal models, where its overexpression led to reduced tumor growth and metastasis, as well as decreased PD-L1 expression [PMC9659572]. Furthermore, hsa-mir-326 overexpression has been linked to an increased infiltration of CD8+ cells and a higher population of TNF-α+ IFN-γ+ CD8+ T-cells within tumor tissues [PMC9659572]. In the context of CML, patients who responded to treatment exhibited significantly higher levels of hsa-mir-326 compared to those who did not respond [PMC7794682]. This suggests that hsa-mir-326 may play a role in the response to treatment in CML and could potentially serve as a biomarker for treatment efficacy or as a therapeutic target.
mRNA interactions
45 total
Genome locations
Gene Ontology annotations
Ancestor Chart
Loading ontology ancestors...
Failed to load QuickGO Ancestor chart
Sequence
Sequence features are shown above as colored rectangles.
Zoom in and click to view details, or
Reset
